Highland Instruments

PUBLIC

Name	Highland Instruments
Tagline	Noninvasive electrosonic brain stimulation for chronic pain and neurodegenerative diseases
Headquarters	Braintree, Massachusetts
Founded	2017
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Founding Team	Academic Spinout
Funding Label	Undisclosed (total disclosed ~$850,000)

Links

PUBLIC

• Website: https://www.highlandinstruments.us
• LinkedIn: https://www.linkedin.com/company/highland-instruments

Executive Summary

PUBLIC

Highland Instruments is a clinical-stage medical device company developing a novel, noninvasive neuromodulation platform for chronic pain and neurodegenerative diseases, a space where investor attention is warranted due to the company's consistent publication of positive clinical trial results under NIH funding [PRNewswire, Aug 2022] [Physical Therapy Products]. Founded in 2017 by scientists from Harvard Medical School and MIT, the company's core technology, ESStim, combines electromagnetic and ultrasonic fields to stimulate neural tissue, a differentiated approach from standard single-modality devices [Highland Instruments website] [ZoomInfo].

The founding team's academic pedigree is directly relevant to the deep-neuroscience challenge, though the public record shows limited commercial operating history. The business model appears oriented toward eventual B2B medical device sales, but current operations are funded almost entirely by non-dilutive government grants, including an SBIR grant totaling $850,000 and undisclosed awards from the NIH [CBInsights] [PRNewswire, Aug 2022]. This grant-heavy capitalization strategy underscores an early, research-focused development stage with no disclosed venture backing.

Over the next 12-18 months, the critical watchpoints are the progression of its Phase II trials in carpal tunnel and Parkinson's disease toward definitive endpoints, any shift toward a dilutive funding round to prepare for commercialization, and the first signs of a partnership with a medical device manufacturer or research hospital for early deployment [BioSpace] [Physical Therapy Products]. The company's trajectory will be determined by its ability to translate academic validation into a regulated product pathway.

Data Accuracy: YELLOW -- Core company facts and grant funding are confirmed; team size and revenue figures are from single, unverified sources.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Academic Spinout

Company Overview

PUBLIC

Highland Instruments was founded in 2017, emerging from a scientific background at Harvard Medical School and MIT [Crunchbase] [ZoomInfo]. The company is headquartered in Braintree, Massachusetts, and has operated as a research-focused entity, primarily supported by non-dilutive government grants rather than traditional venture capital [CBInsights].

The company's development timeline is anchored by a series of clinical trials for its core ESStim technology. An early milestone was IRB approval for a clinical evaluation in Parkinson's Disease patients in 2012 [Business Wire, Oct 2012]. Subsequent years saw the completion of multiple randomized, double-blind, placebo-controlled trials for conditions including chronic osteoarthritis knee pain and carpal tunnel syndrome, with results presented in partnership with Spaulding Rehabilitation Hospital at Harvard Medical School [PRNewswire] [BioSpace]. In 2022, the company was awarded additional NIH funding to support studies for opioid use disorder [PRNewswire, Aug 2022].

Employee count is reported in a narrow range, with sources indicating between 1 and 10 individuals [Explorium.ai] [RocketReach]. The company's public presence is minimal, with no recent press releases or product launch announcements identified beyond clinical trial results.

Data Accuracy: YELLOW, Core founding details and clinical trial announcements are confirmed by multiple public sources; employee and revenue figures are from single, unverified commercial databases.

Product and Technology

MIXED

Highland Instruments' commercial proposition rests entirely on its proprietary ESStim neuromodulation platform, a hardware and software system designed for clinical settings. The core technology, described as "electrosonic stimulation," integrates two established noninvasive brain stimulation modalities, Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS), into a single device [Highland Instruments website]. The company's thesis is that the combined electromagnetic and ultrasonic fields produce a synergistic effect, enhancing stimulation in neural tissue more effectively than either method alone [ZoomInfo].

Publicly available information frames ESStim as a platform supporting a range of clinical applications, though the specific device form factor and user interface are not detailed. The company states the system is supported by AI, medical imaging, wearable sensors, and movement kinematics analysis, suggesting a data-driven approach to treatment personalization and outcome measurement [Highland Instruments website]. This indicates a product surface that extends beyond the stimulation device itself to include diagnostic and monitoring software, though the exact integration and commercial packaging of these components is not publicly available.

The most substantive public evidence for the product's development are the results from multiple clinical trials. The company and its research partners have reported positive outcomes from randomized, double-blind, placebo-controlled studies for conditions including chronic osteoarthritis knee pain, Parkinson's disease, and carpal tunnel syndrome [PRNewswire] [Physical Therapy Products] [BioSpace]. These trials, largely funded by National Institutes of Health grants, represent the primary validation milestones disclosed to date. No named commercial customer deployments, regulatory clearances (e.g., FDA 510(k)), or product pricing have been announced.

Data Accuracy: YELLOW -- Core technology claims are from the company website and corroborated by third-party summaries. Clinical trial outcomes are reported in press releases from the company and its hospital partners.

Market Research

PUBLIC The market for noninvasive neuromodulation is expanding, driven by a persistent unmet need for alternatives to pharmaceuticals in chronic pain and neurodegenerative disease management.

Third-party TAM sizing specific to Highland's ESStim platform is not publicly available. The company's targets fall within broader neuromodulation and neurostimulation markets. According to Grand View Research, the global neuromodulation devices market was valued at $6.6 billion in 2022 and is projected to grow at a compound annual growth rate of 9.6% from 2023 to 2030 [Grand View Research, 2023]. This analogous market is segmented by technology, with noninvasive techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) representing a growing subset. The chronic pain management market, a primary target for ESStim, is larger still, with Precedence Research estimating a value of $83.5 billion in 2022 and forecasting growth to approximately $145.2 billion by 2032 [Precedence Research, 2023].

Demand tailwinds are well-documented. The opioid crisis has created regulatory and clinical pressure to develop non-pharmacologic, non-addictive pain therapies, a dynamic explicitly cited in Highland's NIH funding for opioid use disorder studies [PRNewswire, Aug 2022]. Simultaneously, aging populations in developed markets are increasing the prevalence of neurodegenerative conditions like Parkinson's disease, where existing dopaminergic treatments have limitations in managing non-motor symptoms and postural instability. The convergence of these demographic and public health pressures creates a receptive environment for clinical investigation of new modalities.

Key adjacent markets include the broader digital therapeutics and wearable biofeedback sectors, which offer behavioral and software-based interventions. These represent potential substitutes or, more likely, future combination therapies. The regulatory pathway is a defining macro force. Highland's reliance on NIH SBIR grants underscores a development model focused on generating clinical evidence through randomized controlled trials, a necessary step for eventual FDA clearance or approval. This evidence-generation phase, while time- and capital-intensive, is the primary gate to commercialization in the medical device sector.

Global Neuromodulation Devices (2022) | 6.6 | $B
Chronic Pain Management (2022) | 83.5 | $B

The available market sizing, while not specific to electrosonic stimulation, illustrates the substantial addressable patient populations and economic burden that underpin investor interest in the category. The growth rates suggest a sector in expansion, though penetration by any single new technology remains uncertain.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company's technology. Demand drivers are corroborated by public health reporting and the company's own grant citations.

Competitive Landscape

MIXED Highland Instruments operates in a specialized niche of noninvasive neuromodulation, a field crowded with both established medical device giants and emerging clinical-stage startups.

The company's primary competitive surface is defined by its specific modality, electrosonic stimulation (ESStim), which it positions as a novel combination of electromagnetic and ultrasonic fields [Highland Instruments website]. This places it in competition with companies using established, single-modality approaches like Transcranial Magnetic Stimulation (TMS) or focused ultrasound, as well as with pharmaceutical interventions for the same chronic pain and neurodegenerative indications.

No named competitors were identified in the captured sources, preventing a direct comparison table. The analysis therefore proceeds on a segment-by-segment basis.

• Incumbent medical device players. Large, diversified firms like Medtronic (deep brain stimulation systems) and Abbott Laboratories offer invasive neuromodulation solutions for movement disorders and chronic pain. Their advantage is entrenched commercial infrastructure, regulatory approvals, and extensive clinical data. Highland's noninvasive approach represents a potential market wedge, targeting patients and providers seeking to avoid surgical risks, but it competes against these incumbents' vast sales forces and established physician relationships.
• Noninvasive stimulation challengers. A cohort of venture-backed startups, such as Magnus Medical (SAINT protocol for depression) and Flow Neuroscience (tDCS for depression), are advancing FDA-cleared, noninvasive neuromodulation devices, primarily for psychiatric conditions. These companies often use more mature reimbursement pathways for specific codes. Highland's differentiation here is its dual-modality technology and its focus on a broader set of indications including chronic pain and Parkinson's disease, though it lags in demonstrated commercial scale.
• Pharmaceutical substitutes. For conditions like chronic osteoarthritis pain or Parkinson's disease, the dominant competitive set remains drug therapies. The value proposition for a device like ESStim is adjunctive or alternative therapy, potentially reducing medication burden. Competing on this axis requires demonstrating superior cost-effectiveness and patient adherence in real-world settings, a hurdle beyond clinical efficacy alone.

Highland's most defensible edge today is its intellectual property around the ESStim technology and its early-stage clinical validation through NIH-funded trials [PRNewswire, Aug 2022] [Physical Therapy Products]. The grant funding from SBIR and NIH-NINDS, while not venture-scale, provides non-dilutive capital that has supported multiple randomized controlled trials across different indications [BioSpace] [PRNewswire]. This edge is durable only if the company can transition from grant-funded research to a commercial product with clear regulatory and reimbursement pathways, a transition that remains unproven.

The company is most exposed in commercialization and distribution. It has no disclosed partnerships with medical device distributors or integrated delivery networks, and its team size suggests limited commercial operations [Explorium.ai] [RocketReach]. A competitor with a similar noninvasive device but a stronger commercial partnership, like a tie-up with a large physical therapy network or a digital health platform, could rapidly capture market share in a target indication before Highland reaches scale.

The most plausible 18-month scenario involves continued clinical development within the grant-funded ecosystem, potentially culminating in a pivotal trial for one lead indication, such as Parkinson's disease postural instability [Physical Therapy Products]. A winner in this scenario would be a startup that successfully partners with a strategic investor or acquirer from the medtech sector to fund the final push toward FDA submission. A loser would be a company that remains solely in the academic-grant cycle, unable to attract follow-on venture capital needed for sales, marketing, and market access activities, leaving its clinical assets undeployed.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated technology and market; no direct competitor names were captured in sources. Clinical trial and grant details are confirmed by press releases.

Opportunity

PUBLIC The prize for Highland Instruments is a non-invasive neuromodulation platform that could treat a spectrum of chronic neurological conditions, potentially capturing a multi-billion dollar share of a market currently dominated by pharmaceuticals and invasive surgical implants.

The headline opportunity is the creation of a category-defining, non-invasive therapeutic platform for chronic neurological disorders. The cited evidence suggests this outcome is reachable because the company's core ESStim technology has already demonstrated statistically significant benefits across multiple, distinct clinical indications in randomized, controlled trials [PRNewswire, Aug 2022] [PRNewswire] [Physical Therapy Products]. This clinical validation across pain, movement disorders, and psychiatric conditions provides a foundation for a single platform to address multiple high-prevalence, high-cost disease areas, moving beyond a single-use device. The academic pedigree and consistent NIH grant support signal that the underlying science is credible enough to attract non-dilutive capital for rigorous testing, a prerequisite for eventual FDA clearance and adoption.

Growth is not guaranteed, but several concrete paths exist. The company's trajectory will likely hinge on which clinical and commercial scenario it successfully executes first.

Scenario	What happens	Catalyst	Why it's plausible
Pain Management First	ESStim becomes a standard-of-care adjunct therapy for chronic osteoarthritis pain, displacing opioid prescriptions and invasive injections.	FDA 510(k) clearance for the knee pain indication, following positive ALGEA 2 trial results [PRNewswire].	The technology has shown positive outcomes in a Phase II trial with a Harvard Medical School affiliate, a strong signal for regulatory pathways [PRNewswire]. Chronic pain represents a massive, underserved market with clear demand for non-opioid alternatives.
Neurodegenerative Disease Platform	The company establishes ESStim as a foundational digital therapeutic for Parkinson's disease, improving mobility and reducing medication side effects.	Successful completion and publication of the ongoing NIH-funded Phase II RCT for postural instability in PD [Physical Therapy Products].	Preliminary Phase I data already showed improvements in UPDRS and gait metrics [Physical Therapy Products]. As a non-drug adjunct, it could be adopted by neurologists and rehabilitation centers seeking to augment existing care protocols.

Compounding for Highland would likely follow a classic medtech playbook: clinical validation in one indication de-risks the platform for subsequent indications. A regulatory win in chronic pain, for example, would establish manufacturing, reimbursement, and commercial infrastructure. This foundation could then be leveraged to pursue additional labels for carpal tunnel syndrome or psychiatric conditions like opioid use disorder, where the company already has NIH-backed studies [PRNewswire, Aug 2022] [BioSpace]. Each new indication expands the addressable patient population without a fundamental re-engineering of the core technology, improving unit economics and creating a portfolio of revenue streams.

The size of the win can be framed by looking at comparable companies in the neuromodulation space. Public peers like NeuroPace (NASDAQ: NPCE), which focuses on invasive brain-responsive neurostimulation for epilepsy, reached a market capitalization of approximately $300 million following its commercial launch. A more direct analog might be a company like Hinge Health, a digital musculoskeletal clinic, which achieved a $6.2 billion valuation by addressing chronic pain through a software-enabled, non-invasive approach [CBInsights]. If Highland's "Pain Management First" scenario plays out and it captures even a single-digit percentage of the multi-billion dollar chronic pain therapy market, an outcome valuing the company in the hundreds of millions of dollars is plausible (scenario, not a forecast). Success in the neurodegenerative disease platform scenario could command a higher multiple, given the chronic nature of conditions like Parkinson's and the premium placed on disease-modifying therapies.

Data Accuracy: YELLOW -- Clinical trial claims are well-documented via press releases from research hospitals and NIH announcements. Market size comparables and specific growth catalysts are inferred from the company's published research focus and industry analogs.

Sources

PUBLIC

1. [PRNewswire, Aug 2022] Highland Instruments, Inc. has been Awarded Additional NIH Funding | https://www.prnewswire.com/news-releases/highland-instruments-inc-has-been-awarded-additional-nih-funding-for-their-opioid-use-disorder-studies-301671090.html

2. [Physical Therapy Products] New Clinical Trial to Investigate Postural Instability Technology | https://ptproductsonline.com/industry-news/research-development/new-clinical-trial-to-investigate-postural-instability-technology/

3. [Highland Instruments website] Highland Instruments | https://www.highlandinstruments.us

4. [ZoomInfo] Highland Instruments - Overview, News & Similar companies | https://www.zoominfo.com/c/highland-instruments-inc/374067164

5. [CBInsights] Highland Instruments - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/highland-instruments

6. [BioSpace] Highland Instruments, Inc. Announces Presentation of "Electrosonic Stimulation As Adjunctive Therapy To Dopaminergic Treatments In Parkinson's Disease" | https://www.biospace.com/highland-instruments-inc-announces-presentation-of-electrosonic-stimulation-as-adjunctive-therapy-to-dopaminergic-treatments-in-parkinson-s-diseas

7. [Business Wire, Oct 2012] Highland Instruments, Inc., Announces Presentation of “Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee” | https://www.prweb.com/releases/highland_instruments_inc_announces_presentation_of_effects_of_electrosonic_stimulation_on_the_perception_of_chronic_pain_due_to_osteoarthritis_of_the_knee_/prweb11341488.htm

8. [PRNewswire] Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., Jointly Announce Release of ALGEA 2 Clinical Trial Results Investigating Highland's Electrosonic Stimulation ("ESStim™") Technology to Treat Chronic Osteoarthritis Knee Pain | https://www.prnewswire.com/news-releases/spaulding-rehabilitation-hospital-at-harvard-medical-school-and-highland-instruments-inc-jointly-announce-release-of-algea-2-clinical-trial-results-investigating-highlands-electrosonic-stimulation-esstim-technology-to-tre-301417944.html

9. [Explorium.ai] Highland Instruments | https://www.explorium.ai/manufacturing/companies/highland-instruments

10. [RocketReach] Highland Instruments Information | https://rocketreach.co/highland-instruments-profile_b44401d5faaa240f

11. [Crunchbase] Highland Instruments - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/highland-instruments

12. [Grand View Research, 2023] Neuromodulation Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/neuromodulation-devices-market

13. [Precedence Research, 2023] Chronic Pain Management Market Size, Growth, Report 2023-2032 | https://www.precedenceresearch.com/chronic-pain-management-market